Spago Nanomedical AB (publ), formerly Spago Imaging publ AB, is a Sweden-based biotechnology company. The Company is a nanomedicine company in clinical development phase, developing products for diagnostics and treatment of life-threatening and debilitating diseases. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under Preclinical development stage. The Company’s operations are based on a patented material for the design of functional nanoparticles that accumulate physiologically in tumors, thus enabling higher precision in image diagnostics and treatment of cancer and other severe diseases.
Back to dashboard
Company Information
About this company
Key people
Click to see more
Key facts
- Shares in issue808.59m
- EPICSPAGO
- ISINSE0004899474
- LocationSweden
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market capSEK 90.62m
- Employees5
- ExchangeStockholm Stock Exchange
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.